Vanguard Group Inc. Has $224.40 Million Stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Vanguard Group Inc. grew its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 0.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 132,780,095 shares of the company’s stock after buying an additional 463,096 shares during the quarter. Vanguard Group Inc. owned 6.17% of Ginkgo Bioworks worth $224,398,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank acquired a new position in Ginkgo Bioworks during the fourth quarter valued at approximately $24,967,000. Exchange Traded Concepts LLC raised its holdings in shares of Ginkgo Bioworks by 27.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 507,814 shares of the company’s stock worth $858,000 after buying an additional 109,927 shares in the last quarter. Pinebridge Investments L.P. lifted its position in shares of Ginkgo Bioworks by 358.2% during the 4th quarter. Pinebridge Investments L.P. now owns 140,935 shares of the company’s stock worth $238,000 after buying an additional 110,177 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its stake in Ginkgo Bioworks by 79.2% in the third quarter. B. Riley Wealth Advisors Inc. now owns 115,803 shares of the company’s stock valued at $210,000 after buying an additional 51,170 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in Ginkgo Bioworks by 5.2% in the fourth quarter. Nordea Investment Management AB now owns 4,412,457 shares of the company’s stock valued at $7,435,000 after acquiring an additional 216,434 shares during the last quarter. Institutional investors own 78.63% of the company’s stock.

Insider Transactions at Ginkgo Bioworks

In related news, Director Harry Sloan bought 297,619 shares of Ginkgo Bioworks stock in a transaction that occurred on Tuesday, May 14th. The shares were acquired at an average cost of $0.91 per share, for a total transaction of $270,833.29. Following the completion of the acquisition, the director now directly owns 718,540 shares of the company’s stock, valued at approximately $653,871.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Harry Sloan purchased 297,619 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were purchased at an average price of $0.91 per share, for a total transaction of $270,833.29. Following the transaction, the director now owns 718,540 shares of the company’s stock, valued at $653,871.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Mark E. Dmytruk sold 47,806 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $0.84, for a total transaction of $40,157.04. Following the completion of the sale, the insider now directly owns 925,400 shares in the company, valued at $777,336. The disclosure for this sale can be found here. Insiders sold 326,246 shares of company stock worth $267,499 over the last ninety days. 15.05% of the stock is owned by insiders.

Ginkgo Bioworks Stock Performance

Shares of NYSE DNA opened at $0.32 on Tuesday. The firm has a 50 day moving average price of $0.64 and a two-hundred day moving average price of $1.07. The stock has a market cap of $712.25 million, a P/E ratio of -0.73 and a beta of 1.14. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $0.26 and a 52-week high of $2.55.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $37.94 million during the quarter, compared to the consensus estimate of $45.50 million. Ginkgo Bioworks had a negative return on equity of 56.09% and a negative net margin of 409.11%. During the same period in the prior year, the business posted ($0.08) earnings per share. Analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. BTIG Research reduced their price target on shares of Ginkgo Bioworks from $0.50 to $0.20 and set a “sell” rating on the stock in a research note on Wednesday, June 26th. William Blair cut shares of Ginkgo Bioworks from a “market perform” rating to an “underperform” rating in a research note on Friday, May 10th. Finally, Morgan Stanley dropped their price target on Ginkgo Bioworks from $2.00 to $1.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 15th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Ginkgo Bioworks presently has an average rating of “Hold” and a consensus price target of $1.56.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.